Ziarco Launches with $27M Series A, Assets from Pfizer
By Nuala Moran
Monday, November 5, 2012
LONDON Four Pfizer Inc. scientists and executives have formed a new company specializing in inflammatory and allergic diseases around assets deemed surplus to requirements following the closure of the U.S. pharma company's UK R&D center in Sandwich, Kent.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.